NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.0352
-0.0003 (-0.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.0355
Open0.0350
Bid0.0000 x 900
Ask0.0000 x 2200
Day's Range0.0340 - 0.0359
52 Week Range0.0300 - 1.8900
Volume7,516,318
Avg. Volume34,740,734
Market Cap71.951M
Beta2.08
PE Ratio (TTM)N/A
EPS (TTM)-0.7240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • Associated Press6 days ago

    Neovasc: 2Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 4 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, were less than 1 cent on a per-share basis. The ...

  • PR Newswire6 days ago

    Neovasc Announces Second Quarter 2018 Financial Results

    NASDAQ, TSX: NVCN First implant of a Neovasc Reducer™ in a U.S. patient Reducer Q2, 2018 revenue up 64% over Q2, 2017 and at 108% of Q2, 2018 plan Tiara™ featured in live case at 11th Annual TVT conference ...

  • CNW Group6 days ago

    Neovasc Announces Second Quarter 2018 Financial Results

    Neovasc Announces Second Quarter 2018 Financial Results

  • What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?
    Simply Wall St.6 days ago

    What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?

    In this article, I’m going to take a look at Neovasc Inc’s (TSE:NVCN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • ACCESSWIRE7 days ago

    Neovasc Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Neovasc Inc. (NASDAQ: NVCN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...

  • PR Newswire7 days ago

    Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 8, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Group7 days ago

    Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference

    Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference

  • ACCESSWIRE9 days ago

    Biotechnology Stocks Trending on New Developments 2018

    CORAL GABLES, FL / ACCESSWIRE / August 6, 2018 / Earnings season continues to roll on this week as a number of companies report second quarter results. In fact over the last 3 months, the Health Care Select Sector SPDR Fund (XLV) has been climbing back toward its 52 week high. Likewise, both the SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology Index ETF (IBB) have maintained their 2018 uptrend despite periodic consolidation throughout the year.

  • PR Newswire9 days ago

    Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology

    VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study" in the International Journal of Cardiology, which is available online at: https://doi.org/10.1016/j.ijcard.2018.06.116. In this published study, the safety and effectiveness of the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device designed for the treatment of refractory angina, was evaluated using a real-world cohort of 141 patients in three high-volume medical centers in Milan, Tel Aviv and Antwerp. The researchers aimed to evaluate the efficacy of the Reducer in improving quality of life and reducing symptoms of angina pectoris in 141 consecutive patients suffering from coronary artery disease and chronic refractory angina.

  • CNW Group9 days ago

    Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology

    VANCOUVER , Aug. 6, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study" in the International Journal of Cardiology, which is available online at: https://doi.org/10.1016/j.ijcard.2018.06.116. In this published study, the safety and effectiveness of the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device designed for the treatment of refractory angina, was evaluated using a real-world cohort of 141 patients in three high-volume medical centers in Milan , Tel Aviv and Antwerp . The researchers aimed to evaluate the efficacy of the Reducer in improving quality of life and reducing symptoms of angina pectoris in 141 consecutive patients suffering from coronary artery disease and chronic refractory angina.

  • PR Newswire9 days ago

    Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 6, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Group9 days ago

    Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

    Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

  • CNW Group11 days ago

    Neovasc Announces Collaboration and Licensing Agreement with Penn Medicine and the Gorman Cardiovascular Research Group

    VANCOUVER , Aug. 3, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has entered into a collaboration and licensing agreement relating to certain know-how developed by Penn Medicine and the Gorman Cardiovascular Research Group at the University of Pennsylvania (together, "Penn"). This Agreement resolves certain potential claims against the Company that were described in the Company's Annual Report on Form 20-F and management's discussion and analysis for Q1. This agreement does not impact either Penn or Neovasc's patent rights. Tiara™ ("Tiara") is Neovasc's minimally invasive transcatheter device for patients who experience severe mitral regurgitation ("MR").

  • PR Newswire11 days ago

    Neovasc Announces Collaboration and Licensing Agreement with Penn Medicine and the Gorman Cardiovascular Research Group

    VANCOUVER, Aug. 3, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has entered into a collaboration and licensing agreement relating to certain know-how developed by Penn Medicine and the Gorman Cardiovascular Research Group at the University of Pennsylvania (together, "Penn"). This Agreement resolves certain potential claims against the Company that were described in the Company's Annual Report on Form 20-F and management's discussion and analysis for Q1. This agreement does not impact either Penn or Neovasc's patent rights. Tiara™ ("Tiara") is Neovasc's minimally invasive transcatheter device for patients who experience severe mitral regurgitation ("MR").

  • CNW Group13 days ago

    Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast

    Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast

  • ACCESSWIRE26 days ago

    Today’s Free Research Reports Coverage on Neovasc and Three More Healthcare Stocks

    Under assessment this morning are these four equities: Myomo Inc. (NYSE AMER: MYO), Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), and Insulet Corp. (NASDAQ: PODD). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • PR Newswire29 days ago

    Nasdaq Schedules Hearing to Consider Neovasc's Appeal of Delisting Determination

    VANCOUVER, July 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has scheduled an oral hearing for August 30, 2018, at which the Nasdaq Hearings Panel (the "Panel") will consider Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Neovasc's securities from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement. Words and phrases such as "believes", "can", "scheduled" and "will", and similar words or expressions, are intended to identify these forward-looking statements.

  • CNW Group29 days ago

    Nasdaq Schedules Hearing to Consider Neovasc's Appeal of Delisting Determination

    VANCOUVER , July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has scheduled an oral hearing for August 30, 2018 , at which the Nasdaq Hearings Panel (the "Panel") will consider Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Neovasc's securities from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement. Words and phrases such as "believes", "can", "scheduled" and "will", and similar words or expressions, are intended to identify these forward-looking statements.

  • CNW Grouplast month

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

  • PR Newswirelast month

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

    NASDAQ, TSX: NVCN VANCOUVER , July 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short ...

  • PR Newswirelast month

    Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

    VANCOUVER, July 9, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will request a hearing before the Nasdaq Hearings Panel (the "Panel") as the next step in the process to seeking an additional 180-day extension for compliance with the US$1 minimum bid price requirement.  On July 6, 2018, the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff has determined to delist the Company's common shares from Nasdaq Capital Market unless the Company requests a hearing before the Panel by July 13, 2018, which the Company will do. As previously announced, the Company has already received shareholder approval to execute a reverse stock split, common share consolidation, to enable the Company to regain compliance with the minimum bid price requirement.  However, the Company is seeking an additional 180-day extension so that the Board and management can effect the reverse stock split at a time, during that extension, if granted, that is in the best interest of the Company and its stakeholders.

  • CNW Grouplast month

    Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

    VANCOUVER , July 9, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will request a hearing before the Nasdaq Hearings Panel (the "Panel") as the next step in the process to seeking an additional 180-day extension for compliance with the US$1 minimum bid price requirement.  On July 6, 2018 , the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff has determined to delist the Company's common shares from Nasdaq Capital Market unless the Company requests a hearing before the Panel by July 13, 2018 , which the Company will do. As previously announced, the Company has already received shareholder approval to execute a reverse stock split, common share consolidation, to enable the Company to regain compliance with the minimum bid price requirement.  However, the Company is seeking an additional 180-day extension so that the Board and management can effect the reverse stock split at a time, during that extension, if granted, that is in the best interest of the Company and its stakeholders.

  • CNW Grouplast month

    Tiara and Reducer Featured at CSI Frankfurt 2018

    VANCOUVER , July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical devices used for the treatment of refractory angina, were both featured in presentations at the CSI Frankfurt 2018 conference held on June 27-30, 2018 in Frankfurt, Germany . This year, new Reducer clinical data was presented in a scientific session entitled: Structural meets coronary – Reducer for the treatment of refractory angina. The clinical data presented again demonstrated the clinical benefits of the Reducer in improving quality of life of patients suffering from disabling angina, as well as improving exercise capability.

  • PR Newswirelast month

    Tiara and Reducer Featured at CSI Frankfurt 2018

    VANCOUVER, July 2, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical devices used for the treatment of refractory angina, were both featured in presentations at the CSI Frankfurt 2018 conference held on June 27-30, 2018 in Frankfurt, Germany. This year, new Reducer clinical data was presented in a scientific session entitled: Structural meets coronary – Reducer for the treatment of refractory angina. The clinical data presented again demonstrated the clinical benefits of the Reducer in improving quality of life of patients suffering from disabling angina, as well as improving exercise capability.

  • PR Newswirelast month

    Neovasc Announces Filing of Shelf Prospectus and Form F-10 Registration Statement

    VANCOUVER, July 2, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System. "This new base shelf prospectus will replace our existing base shelf prospectus that expires on July 9, 2018," commented Chris Clark, Neovasc's Chief Financial Officer. The base shelf prospectus and the Registration Statement, once clear and effective, respectively, will allow Neovasc to offer up to U.S.$100,000,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time over a 25-month period after Canadian securities regulatory authorities have issued a receipt for the final short form base shelf prospectus.